Ting-Ting Ye1, Yin-Long Yang2, Xin-Ying Liu3, Qian-Qing Ji2, Yi-Fei Pan2, You-Qun Xiang2. 1. Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang, China. 2. Department of Surgical Oncology, The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000, Zhejiang, China. 3. Department of Ultrasound, Zhejiang Provincial People's Hospital Hangzhou 310014, Zhejiang, China.
Abstract
UNLABELLED: Circulating microRNAs show aberrant expression in patients with cancer. The aim of this study was to investigate the prognostic value of circulating microRNA-21 (miR-21) in digestive system cancers. METHODS: All the eligible studies were searched by Medline and EMBASE. The hazard ratios (HRs) for overall survival (OS), which compared the expression levels of circulating miR-21 in patients with digestive cancer was extracted and estimated. Pooled HRs and 95% confidence intervals (CI) were calculated. Then a meta-analysis was performed to clarify the prognostic value of the miR-21. RESULTS: A total of seven studies involving 907 subjects were included. The results suggested that higher circulating miR-21 could predict worse OS outcome with the pooled HR of 2.19 (95% CI 1.01-4.75, P = 0.05) in digestive system cancers. Subgroup analysis by ethnicity indicated circulating miR-21 was associated with OS in patients with digestive cancer among Asians with the pooled HR of 2.90 (95% CI 1.30-6.45, P = 0.009). However, subgroup analysis by digestive system site revealed that there is no associated with OS in patients with colorectal cancer with the pooled HR of 1.34 (95% CI 0.45-4.00, P = 0.60). CONCLUSION: The present findings suggest that circulating miR-21 is associated with poor survival in patients with digestive cancer and could be a prognostic biomarker for those patients.
UNLABELLED: Circulating microRNAs show aberrant expression in patients with cancer. The aim of this study was to investigate the prognostic value of circulating microRNA-21 (miR-21) in digestive system cancers. METHODS: All the eligible studies were searched by Medline and EMBASE. The hazard ratios (HRs) for overall survival (OS), which compared the expression levels of circulating miR-21 in patients with digestive cancer was extracted and estimated. Pooled HRs and 95% confidence intervals (CI) were calculated. Then a meta-analysis was performed to clarify the prognostic value of the miR-21. RESULTS: A total of seven studies involving 907 subjects were included. The results suggested that higher circulating miR-21 could predict worse OS outcome with the pooled HR of 2.19 (95% CI 1.01-4.75, P = 0.05) in digestive system cancers. Subgroup analysis by ethnicity indicated circulating miR-21 was associated with OS in patients with digestive cancer among Asians with the pooled HR of 2.90 (95% CI 1.30-6.45, P = 0.009). However, subgroup analysis by digestive system site revealed that there is no associated with OS in patients with colorectal cancer with the pooled HR of 1.34 (95% CI 0.45-4.00, P = 0.60). CONCLUSION: The present findings suggest that circulating miR-21 is associated with poor survival in patients with digestive cancer and could be a prognostic biomarker for those patients.
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Pablo Menéndez; David Padilla; Pedro Villarejo; Teodoro Palomino; Patricia Nieto; José M Menéndez; José A Rodríguez-Montes Journal: J Surg Oncol Date: 2013-08-23 Impact factor: 3.454
Authors: Martha L Slattery; Jennifer S Herrick; Lila E Mullany; Nicola Valeri; John Stevens; Bette J Caan; Wade Samowitz; Roger K Wolff Journal: Int J Cancer Date: 2014-12-16 Impact factor: 7.396
Authors: Martha L Slattery; Jennifer S Herrick; Daniel F Pellatt; Lila E Mullany; John R Stevens; Erica Wolff; Michael D Hoffman; Roger K Wolff; Wade Samowitz Journal: Oncotarget Date: 2016-09-13